news Regen completes preclinical experimentation for its NR2F6 checkpoint inhibitor 26 February 2016 | By Victoria White Regen has recently filed two patent applications covering the molecular pathways activated by NR2F6 silencing...
news Studies suggest major role for Regen’s NR2F6 target in controlling key immune functions 18 February 2016 | By Victoria White The results demonstrate that suppression of NR2F6 in T-cells results in increased expression of key immune stimulatory proteins IL-17 and IL-18...
news Regen BioPharma and NCATS to research the NR2F6 protein 20 January 2016 | By Victoria White The collaboration will focus on identifying ligands for NR2F6 using Regen's screening methodology and the expertise and unique chemical libraries of NCATS...
news Regen BioPharma initiates NR2F6 T-cell immunotherapy preclinical studies 12 November 2015 | By Victoria White The studies will evaluate the utilisation of NR2F6 gene silencing as a means of stimulating the immune system in cancer patients...
news Regen BioPharma reports successful dosing of HemaXellerate in FDA-requested GLP animal study 10 July 2015 | By Victoria White Regen BioPharma has reported the successful dosing of mice lacking an immune system in a safety and tolerability study with HemaXellerate...